30 April 2014
Vol 6, Issue 234

About The Cover

Cover image expansion

ONLINE COVER Race for the Cures. Although the discovery and development of biomedical products is measured in years rather than seconds, stakeholders, including patients, still have one eye on the clock and one on the finish line—and all are aware that clinical studies with traditional patient cohorts aren't breaking any efficiency records. In this week's Commentary Bowton and colleagues describe a cost-effective alternative approach for translational pharmacogenomic studies—the pairing of disease-agnostic biobank specimens with patients' electronic medical records. [CREDIT: SZACHO/ISTOCKPHOTO]